- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Upstream Bio reports Q3 results | 1 | Seeking Alpha | ||
| Di | Upstream Bio Reports Third Quarter 2026 Financial Results and Highlights Continued Progress | 1 | GlobeNewswire (USA) | ||
| UPSTREAM BIO Aktie jetzt für 0€ handeln | |||||
| Di | Upstream Bio, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| Di | Upstream Bio, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 08.09. | Upstream Bio stock jumps 8% on Phase 2 severe asthma data | 2 | Seeking Alpha | ||
| 08.09. | Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026 | 255 | GlobeNewswire (Europe) | - Verekitug, 100 mg dosed every 12 weeks, reduced AAER by 56% compared to placebo in patients with severe asthma - - Verekitug also delivered clinically meaningful improvements in lung function (FEV1)... ► Artikel lesen | |
| 01.09. | Upstream Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 11.08. | Upstream Bio, Inc. reports Q2 results | 1 | Seeking Alpha | ||
| 11.08. | Upstream Bio, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 11.08. | Upstream Bio, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 14.06. | Upstream Bio präsentiert positive Phase-2-Studiendaten für Verekitug | 4 | Investing.com Deutsch | ||
| 14.06. | Upstream Bio presents positive Phase 2 trial data for verekitug | 2 | Investing.com | ||
| 14.06. | Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026 | 2 | GlobeNewswire (USA) | ||
| 12.06. | JPMorgan stuft Upstream Bio wegen Umsetzungsrisiken herab | 6 | Investing.com Deutsch | ||
| 12.06. | JPMorgan downgrades Upstream Bio stock rating on execution risks | 1 | Investing.com | ||
| 10.06. | Upstream Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.06. | Upstream Bio to Showcase Additional Efficacy Data from the Phase 2 VIBRANT Trial of Verekitug in CRSwNP in Oral Session at EAACI 2026 | 289 | GlobeNewswire (Europe) | WALTHAM, Mass., June 08, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory... ► Artikel lesen | |
| 03.06. | H.C. Wainwright startet Coverage für Upstream Bio mit "Buy" und hohem Kursziel | 5 | Investing.com Deutsch | ||
| 03.06. | H.C. Wainwright initiates Upstream Bio stock coverage with buy rating | 1 | Investing.com | ||
| 01.03. | Upstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual Meeting | 378 | GlobeNewswire (Europe) | - Primary endpoint of endoscopic nasal polyp score (NPS) showed reduction of -1.95 (p in new analysis with adjustment for concomitant rescue therapy use - - Secondary endpoints also provided strong... ► Artikel lesen |
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 2,627 | +0,96 % | Valneva meldet positive Phase-2-Daten für Shigellen-Impfstoff | Valneva hat mit seinem Impfstoffkandidaten S4V2 gegen Shigellose positive Ergebnisse aus zwei klinischen Phase-2-Studien erzielt. In einer US-amerikanischen Studie mit kontrollierter Infektion gesunder... ► Artikel lesen | |
| NOVAVAX | 9,050 | -0,88 % | Novavax, Inc.: Novavax Reports Third Quarter 2026 Financial Results and Operational Highlights | Reports total revenue of $68 million for the third quarter of 2026Raises full-year 2026 Non-GAAP Adjusted Total Revenue by $145 million to $400 million at mid-point and improves GAAP Combined R&D and... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 6,980 | +1,31 % | This Palatin Technologies Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday | ||
| OCUGEN | 0,868 | +2,36 % | Ocugen im Check: OCU400-Deal mit Celairis - jetzt zählt die nächste Stufe | ||
| VIVORYON THERAPEUTICS | 0,728 | +2,82 % | Vivoryon Therapeutics N.V. Reports Q3 2026 Financial Results and Provides Business Update | Vivoryon Therapeutics N.V. Reports Q3 2026 Financial Results and Provides Business Update
Ongoing negotiations with different parties towards securing a partnership or financing for the development... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,317 | +3,93 % | 200 Prozent Ausbeute, 1 geplanter GMP-Partner: Warum NurExone und Made Scientific die Exosomenproduktion skalieren wollen | ||
| SAREPTA THERAPEUTICS | 14,580 | -0,82 % | Sarepta Therapeutics auf Guggenheim-Konferenz: Starker Cashflow finanziert breite Entwicklungspipeline | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 2,040 | +1,44 % | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. - 10-Q, Quarterly Report | ||
| REDHILL BIOPHARMA | 0,375 | -0,03 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -4- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameUS1509643029 CENNTRO... ► Artikel lesen | |
| MYRIAD GENETICS | 5,010 | -1,34 % | Myriad Genetics auf der UBS Global Healthcare Conference: Strategischer Schwenk zur Onkologie vertieft | ||
| MANNKIND | 3,801 | +0,42 % | Cantor Fitzgerald hebt Kursziel für MannKind wegen Tyvaso-Dynamik auf 10 US-Dollar an | ||
| ONCO-INNOVATIONS | 0,141 | +10,52 % | Redwood AI Corp.: Onco-Innovations and Redwood AI Secure Terry Fox Research Institute Grant to Advance AI-Powered SynoGraph Oncology Platform | CALGARY, AB AND VANCOUVER, BC / ACCESS Newswire / September 22, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN:A3EKSZ) ("Onco") and Redwood AI Corp. (CSE:AIRX)(OTCQB:RDWCF)(Frankfurt:Y0N... ► Artikel lesen | |
| NOVOCURE | 10,615 | +0,38 % | Novocure Provides Regulatory Update on U.S. FDA Premarket Approval Application for Optune Mya for Brain Metastases from Non-Small Cell Lung Cancer | Novocure (Nasdaq: NVCR) announced today that it has received a Not Approvable Letter from the U.S. Food and Drug Administration (FDA) in response to its Premarket Approval (PMA) application for Optune... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 5,950 | 0,00 % | Ocular Therapeutix outlines Q4 2026 AXPAXLI NDA plan with $530.6M cash runway into 2028 | ||
| TRAWS PHARMA | 0,224 | -0,27 % | Traws Pharma, Inc. - S-1, General form for registration of securities |
UPSTREAM BIO INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -0,59 % bei einem Aktienkurs von 3,360 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu UPSTREAM BIO INC finden Sie auf Wallstreet Online.